Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Sanofi rated AA by Scope Ratings
Paris, France - September 7, 2017 - Sanofi announced today that the European ratings agency Scope Ratings AG ("Scope") assigned the company a AA long term rating and a S-1+ short-term rating. The outlook is stable.
These ratings confirm Sanofi's high credit quality and provide investors with an increased diversity of independent opinions.
Scope is accredited and regulated by the European Securities and Markets Authority. It is the third credit rating agency to rate Sanofi, as the company is already rated AA by Standard & Poor's and A1 by Moody's. Both ratings have stable outlooks.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Contacts:
| Media Relations Laurence Bollack Tel. : +33 (0)1 53 77 46 46 [email protected] | Investor Relations George Grofik Tel.: +33 (0)1 53 77 45 45 [email protected] |
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/45c5ffcc-43c1-48b7-abed-fd6c70f6f632
